{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:42:42Z","timestamp":1793029362368,"version":"4.5.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:00:00Z","timestamp":1538092800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41584-018-0091-8","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T15:40:10Z","timestamp":1538149210000},"page":"631-640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":194,"title":["Effects of the IL-23\u2013IL-17 pathway on\u00a0bone in spondyloarthritis"],"prefix":"10.1038","volume":"14","author":[{"given":"Ellen M.","family":"Gravallese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,28]]},"reference":[{"key":"91_CR1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/cmi.2015.105","volume":"13","author":"X Song","year":"2016","unstructured":"Song, X., He, X., Li, X. & Qian, Y. The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity. Cell. Mol. Immunol. 13, 418\u2013431 (2016).","journal-title":"Cell. Mol. Immunol."},{"key":"91_CR2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020530","volume":"19","author":"MA Boutet","year":"2018","unstructured":"Boutet, M. A., Nerviani, A., Gallo Afflitto, G. & Pitzalis, C. Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int. J. Mol. Sci. 19, e530 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"91_CR3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrrheum.2017.56","volume":"13","author":"V Ranganathan","year":"2017","unstructured":"Ranganathan, V., Gracey, E., Brown, M. A., Inman, R. D. & Haroon, N. Pathogenesis of ankylosing spondylitis \u2014 recent advances and future directions. Nat. Rev. Rheumatol. 13, 359\u2013367 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"91_CR4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen, S. L., Jain, R., Garg, A. V. & Cua, D. J. The\u00a0IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat. Rev. Immunol. 14, 585\u2013600 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"91_CR5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","volume":"13","author":"B Oppmann","year":"2000","unstructured":"Oppmann, B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715\u2013725 (2000).","journal-title":"Immunity"},{"key":"91_CR6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","volume":"421","author":"DJ Cua","year":"2003","unstructured":"Cua, D. J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744\u2013748 (2003).","journal-title":"Nature"},{"key":"91_CR7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nature11984","volume":"496","author":"C Wu","year":"2013","unstructured":"Wu, C. et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature 496, 513\u2013517 (2013).","journal-title":"Nature"},{"key":"91_CR8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature09447","volume":"467","author":"K Ghoreschi","year":"2010","unstructured":"Ghoreschi, K. et al. Generation of pathogenic T(H)17 cells in the absence of TGF-\u03b2 signalling. Nature 467, 967\u2013971 (2010).","journal-title":"Nature"},{"key":"91_CR9","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/eji.201545598","volume":"45","author":"E Montaldo","year":"2015","unstructured":"Montaldo, E., Juelke, K. & Romagnani, C. Group 3 innate lymphoid cells (ILC3s): Origin, differentiation, and plasticity in humans and mice. Eur. J. Immunol. 45, 2127\u20132182 (2015).","journal-title":"Eur. J. Immunol."},{"key":"91_CR10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/exd.12487","volume":"23","author":"RR Keijsers","year":"2014","unstructured":"Keijsers, R. R., Joosten, I., van Erp, P. E., Koenen, H. J. & van de Kerkhof, P. C. Cellular sources of IL-17 in psoriasis: a paradigm shift? Exp. Dermatol. 23, 799\u2013803 (2014).","journal-title":"Exp. Dermatol."},{"key":"91_CR11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/eji.201646787","volume":"48","author":"W Razawy","year":"2018","unstructured":"Razawy, W., van Driel, M. & Lubberts, E. The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling. Eur. J. Immunol. 48, 220\u2013229 (2018).","journal-title":"Eur. J. Immunol."},{"key":"91_CR12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/jid.2008.233","volume":"129","author":"U Huffmeier","year":"2009","unstructured":"Huffmeier, U. et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J. Invest. Dermatol. 129, 355\u2013358 (2009).","journal-title":"J. Invest. Dermatol."},{"key":"91_CR13","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/ng.2007.17","volume":"39","author":"Wellcome Trust Case Control Consortium","year":"2007","unstructured":"Wellcome Trust Case Control Consortium et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat.\u00a0Genet. 39, 1329\u20131337 (2007).","journal-title":"Nat. Genet."},{"key":"91_CR14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature13835","volume":"518","author":"KK Farh","year":"2015","unstructured":"Farh, K. K. et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518, 337\u2013343 (2015).","journal-title":"Nature"},{"key":"91_CR15","doi-asserted-by":"crossref","DOI":"10.1038\/srep10314","volume":"5","author":"M Uddin","year":"2015","unstructured":"Uddin, M. et al. Integrated genomics identifies convergence of ankylosing spondylitis with global immune mediated disease pathways. Sci. Rep. 5, 10314 (2015).","journal-title":"Sci. Rep."},{"key":"91_CR16","doi-asserted-by":"crossref","first-page":"9560","DOI":"10.1073\/pnas.1017854108","volume":"108","author":"R Sarin","year":"2011","unstructured":"Sarin, R., Wu, X. & Abraham, C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T cell functional responses. Proc. Natl Acad. Sci. USA 108, 9560\u20139565 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"91_CR17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017160","volume":"6","author":"P Meglio Di","year":"2011","unstructured":"Di Meglio, P. et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS ONE 6, e17160 (2011).","journal-title":"PLoS ONE"},{"key":"91_CR18","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1002\/art.34600","volume":"64","author":"LM Duivenvoorde van","year":"2012","unstructured":"van Duivenvoorde, L. M. et al. Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27\/human \u03b22 -microglobulin-transgenic rat model of spondylarthritis. Arthritis Rheum. 64, 3210\u20133219 (2012).","journal-title":"Arthritis Rheum."},{"key":"91_CR19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jbspin.2015.03.019","volume":"83","author":"S Aschermann","year":"2016","unstructured":"Aschermann, S. et al. Presence of HLA-B27 is associated with changes of serum levels of mediators of the Wnt and hedgehog pathway. Joint Bone Spine 83, 43\u201346 (2016).","journal-title":"Joint Bone Spine"},{"key":"91_CR20","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/art.24888","volume":"60","author":"H Appel","year":"2009","unstructured":"Appel, H. et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 60, 3257\u20133262 (2009).","journal-title":"Arthritis Rheum."},{"key":"91_CR21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000451","volume":"3","author":"B Neerinckx","year":"2017","unstructured":"Neerinckx, B., Kollnberger, S., Shaw, J. & Lories, R. No evidence for a direct role of HLA-B27 in pathological bone formation in axial SpA. RMD Open 3, e000451 (2017).","journal-title":"RMD Open"},{"key":"91_CR22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock, J. P. et al. IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4\u2212CD8\u2212 entheseal resident T cells. Nat. Med. 18, 1069\u20131076 (2012).","journal-title":"Nat. Med."},{"key":"91_CR23","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1002\/art.34561","volume":"64","author":"L Utriainen","year":"2012","unstructured":"Utriainen, L. et al. Expression of HLA-B27 causes loss of migratory dendritic cells in a rat model of spondyloarthritis. Arthritis Rheum. 64, 3199\u20133209 (2012).","journal-title":"Arthritis Rheum."},{"key":"91_CR24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/08916934.2014.976630","volume":"48","author":"S Ebihara","year":"2015","unstructured":"Ebihara, S., Date, F., Dong, Y. & Ono, M. Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice. Autoimmunity 48, 259\u2013266 (2015).","journal-title":"Autoimmunity"},{"key":"91_CR25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/s10165-009-0166-0","volume":"19","author":"Y Abe","year":"2009","unstructured":"Abe, Y. et al. Ankylosing enthesitis associated with up-regulated IFN-\u03b3 and IL-17 production in (BXSB\u00d7NZB) F(1) male mice: a new mouse model. Mod. Rheumatol. 19, 316\u2013322 (2009).","journal-title":"Mod. Rheumatol."},{"key":"91_CR26","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/art.24568","volume":"60","author":"H Shen","year":"2009","unstructured":"Shen, H., Goodall, J. C. & Hill Gaston, J. S. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 60, 1647\u20131656 (2009).","journal-title":"Arthritis Rheum."},{"key":"91_CR27","volume":"7","author":"L Zhang","year":"2012","unstructured":"Zhang, L. et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS ONE 7, e31000 (2012).","journal-title":"PLoS ONE"},{"key":"91_CR28","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/art.33507","volume":"64","author":"TJ Kenna","year":"2012","unstructured":"Kenna, T. J. et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 64, 1420\u20131429 (2012).","journal-title":"Arthritis Rheum."},{"key":"91_CR29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","volume":"30","author":"Y Mei","year":"2011","unstructured":"Mei, Y. et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin. Rheumatol. 30, 269\u2013273 (2011).","journal-title":"Clin. Rheumatol."},{"key":"91_CR30","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/ar3817","volume":"14","author":"R Celis","year":"2012","unstructured":"Celis, R. et al. Synovial cytokine expression in psoriatic\u00a0arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res. Ther. 14, R93 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"91_CR31","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","volume":"13","author":"H Appel","year":"2011","unstructured":"Appel, H. et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res. Ther. 13, R95 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"91_CR32","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/art.40150","volume":"69","author":"RJ Cuthbert","year":"2017","unstructured":"Cuthbert, R. J. et al. Brief report: group 3 innate lymphoid cells in human enthesis. Arthritis Rheumatol. 69, 1816\u20131822 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"91_CR33","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten, D. et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382, 1705\u20131713 (2013).","journal-title":"Lancet"},{"key":"91_CR34","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease, P. J. et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N.\u00a0Engl. J. Med. 373, 1329\u20131339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"91_CR35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease, P. J. et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann. Rheum. Dis. 76, 79\u201387 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"91_CR36","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin, C. et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann. Rheum. Dis. 73, 990\u2013999 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"91_CR37","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes, I. B. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382, 780\u2013789 (2013).","journal-title":"Lancet"},{"key":"91_CR38","doi-asserted-by":"publisher","unstructured":"Araujo, E. G. et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin. Arthritis Rheum. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.05.011 (2018).","DOI":"10.1016\/j.semarthrit.2018.05.011"},{"key":"91_CR39","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten, D. et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann. Rheum. Dis. 77, 1295\u20131302 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"91_CR40","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy, D., Hermann, K. G., Callhoff, J., Listing, J. & Sieper, J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann. Rheum. Dis. 73, 817\u2013823 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"91_CR41","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1359\/jbmr.090320","volume":"24","author":"NC Walsh","year":"2009","unstructured":"Walsh, N. C. et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J. Bone Miner. Res. 24, 1572\u20131585 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"91_CR42","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/jbmr.2521","volume":"30","author":"R Kocijan","year":"2015","unstructured":"Kocijan, R. et al. Quantitative and qualitative changes of bone in psoriasis and psoriatic arthritis patients. J.\u00a0Bone Miner. Res. 30, 1775\u20131783 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"91_CR43","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/art.1780350911","volume":"35","author":"JP Devogelaer","year":"1992","unstructured":"Devogelaer, J. P., Maldague, B., Malghem, J. & Nagant de Deuxchaisnes, C. Appendicular and vertebral bone mass in ankylosing spondylitis. A comparison of plain radiographs with single- and dual-photon absorptiometry and with quantitative computed tomography. Arthritis Rheum. 35, 1062\u20131067 (1992).","journal-title":"Arthritis Rheum."},{"key":"91_CR44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/ard.53.2.117","volume":"53","author":"S Donnelly","year":"1994","unstructured":"Donnelly, S. et al. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann. Rheum. Dis. 53, 117\u2013121 (1994).","journal-title":"Ann. Rheum. Dis."},{"key":"91_CR45","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1136\/annrheumdis-2016-210441","volume":"76","author":"A Ogdie","year":"2017","unstructured":"Ogdie, A. et al. The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. Ann. Rheum. Dis. 76, 882\u2013885 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"91_CR46","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1172\/JCI60975","volume":"122","author":"U Harre","year":"2012","unstructured":"Harre, U. et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J. Clin. Invest. 122, 1791\u20131802 (2012).","journal-title":"J. Clin. Invest."},{"key":"91_CR47","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","volume":"73","author":"A Kleyer","year":"2014","unstructured":"Kleyer, A. et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann. Rheum. Dis. 73, 854\u2013860 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"91_CR48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/BOR.0000000000000404","volume":"29","author":"B Neerinckx","year":"2017","unstructured":"Neerinckx, B. & Lories, R. Mechanisms, impact and prevention of pathological bone regeneration in spondyloarthritis. Curr. Opin. Rheumatol. 29, 287\u2013292 (2017).","journal-title":"Curr. Opin. Rheumatol."},{"key":"91_CR49","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/annrheumdis-2014-206347","volume":"75","author":"D Simon","year":"2016","unstructured":"Simon, D. et al. Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. Ann. Rheum. Dis. 75, 660\u2013666 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"91_CR50","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nri2062","volume":"7","author":"H Takayanagi","year":"2007","unstructured":"Takayanagi, H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7, 292\u2013304 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"91_CR51","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/archinte.166.22.2495","volume":"166","author":"G Schett","year":"2006","unstructured":"Schett, G. et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch. Intern. Med. 166, 2495\u20132501 (2006).","journal-title":"Arch. Intern. Med."},{"key":"91_CR52","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P","volume":"43","author":"EM Gravallese","year":"2000","unstructured":"Gravallese, E. M. et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 43, 250\u2013258 (2000).","journal-title":"Arthritis Rheum."},{"key":"91_CR53","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","volume":"397","author":"YY Kong","year":"1999","unstructured":"Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315\u2013323 (1999).","journal-title":"Nature"},{"key":"91_CR54","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/08916930701694717","volume":"41","author":"G Schett","year":"2008","unstructured":"Schett, G. Review: immune cells and mediators of inflammatory arthritis. Autoimmunity 41, 224\u2013229 (2008).","journal-title":"Autoimmunity"},{"key":"91_CR55","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.bor.0000127824.42507.68","volume":"16","author":"NC Walsh","year":"2004","unstructured":"Walsh, N. C. & Gravallese, E. M. Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr. Opin. Rheumatol. 16, 419\u2013427 (2004).","journal-title":"Curr. Opin. Rheumatol."},{"key":"91_CR56","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1136\/annrheumdis-2014-207137","volume":"75","author":"L Danks","year":"2016","unstructured":"Danks, L. et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann. Rheum. Dis. 75, 1187\u20131195 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"91_CR57","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","volume":"58","author":"SB Cohen","year":"2008","unstructured":"Cohen, S. B. et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 58, 1299\u20131309 (2008).","journal-title":"Arthritis Rheum."},{"key":"91_CR58","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/annrheumdis-2015-208052","volume":"75","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi, T. et al. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with rheumatoId arthritis on methotrexate to validate inhibitory effect on bone erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann. Rheum. Dis. 75, 983\u2013990 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"91_CR59","unstructured":"Daiichi Sankyo Company. Daiichi Sankyo obtains approval for additional indication for PRALIA\u00ae subcutaneous injection 60 mg syringe. Daiichi-Sankyo https:\/\/www.daiichisankyo.com\/media_investors\/media_relations\/press_releases\/detail\/006655.html (2017)."},{"key":"91_CR60","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/35046102","volume":"408","author":"H Takayanagi","year":"2000","unstructured":"Takayanagi, H. et al. T cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-\u03b3. Nature 408, 600\u2013605 (2000).","journal-title":"Nature"},{"key":"91_CR61","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/en.2010-1268","volume":"152","author":"H Saleh","year":"2011","unstructured":"Saleh, H. et al. Interleukin-33, a target of parathyroid hormone and oncostatin M, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology 152, 1911\u20131922 (2011).","journal-title":"Endocrinology"},{"key":"91_CR62","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","volume":"103","author":"S Kotake","year":"1999","unstructured":"Kotake, S. et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103, 1345\u20131352 (1999).","journal-title":"J. Clin. Invest."},{"key":"91_CR63","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/j.ajpath.2015.07.017","volume":"185","author":"KW Kim","year":"2015","unstructured":"Kim, K. W., Kim, H. R., Kim, B. M., Cho, M. L. & Lee, S. H. Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis. Am. J. Pathol. 185, 3011\u20133024 (2015).","journal-title":"Am. J. Pathol."},{"key":"91_CR64","doi-asserted-by":"crossref","first-page":"479","DOI":"10.5483\/BMBRep.2013.46.10.141","volume":"46","author":"Y Lee","year":"2013","unstructured":"Lee, Y. The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases. BMB Rep. 46, 479\u2013483 (2013).","journal-title":"BMB Rep."},{"key":"91_CR65","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","volume":"203","author":"K Sato","year":"2006","unstructured":"Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673\u20132682 (2006).","journal-title":"J. Exp. Med."},{"key":"91_CR66","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nm.3432","volume":"20","author":"N Komatsu","year":"2014","unstructured":"Komatsu, N. et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat.\u00a0Med. 20, 62\u201368 (2014).","journal-title":"Nat. Med."},{"key":"91_CR67","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.4049\/jimmunol.1003370","volume":"186","author":"B Pollinger","year":"2011","unstructured":"Pollinger, B. et al. Th17 cells, not IL-17+ \u03b3\u03b4T cells, drive\u00a0arthritic bone destruction in mice and humans. J.\u00a0Immunol. 186, 2602\u20132612 (2011).","journal-title":"J. Immunol."},{"key":"91_CR68","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/jcb.22326","volume":"108","author":"T Yago","year":"2009","unstructured":"Yago, T. et al. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-\u03b1 antibody: a novel mechanism of osteoclastogenesis by IL-17. J. Cell. Biochem. 108, 947\u2013955 (2009).","journal-title":"J. Cell. Biochem."},{"key":"91_CR69","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar2936","volume":"12","author":"IE Adamopoulos","year":"2010","unstructured":"Adamopoulos, I. E. et al. Interleukin-17A upregulates receptor activator of NF-\u03baB on osteoclast precursors. Arthritis Res. Ther. 12, R29 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"91_CR70","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/1529-0131(200109)44:9<2176::AID-ART371>3.0.CO;2-4","volume":"44","author":"Y Katz","year":"2001","unstructured":"Katz, Y., Nadiv, O. & Beer, Y. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a \u201cfine-tuning cytokine\u201d in inflammation processes. Arthritis Rheum. 44, 2176\u20132184 (2001).","journal-title":"Arthritis Rheum."},{"key":"91_CR71","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.160.7.3513","volume":"160","author":"DV Jovanovic","year":"1998","unstructured":"Jovanovic, D. V. et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-\u03b2 and TNF-\u03b1, by human macrophages. J. Immunol. 160, 3513\u20133521 (1998).","journal-title":"J. Immunol."},{"key":"91_CR72","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/art.39685","volume":"68","author":"D Heijde van der","year":"2016","unstructured":"van der Heijde, D. et al. Brief report: Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheumatol. 68, 1914\u20131921 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"91_CR73","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/cdd.2009.74","volume":"16","author":"H Huang","year":"2009","unstructured":"Huang, H. et al. IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling. Cell Death Differ. 16, 1332\u20131343 (2009).","journal-title":"Cell Death Differ."},{"key":"91_CR74","first-page":"425","volume":"5","author":"B Osta","year":"2014","unstructured":"Osta, B., Lavocat, F., Eljaafari, A. & Miossec, P. Effects of interleukin-17A on osteogenic differentiation of isolated human mesenchymal stem cells. Front. Immunol. 5, 425 (2014).","journal-title":"Front. Immunol."},{"key":"91_CR75","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/eji.200939670","volume":"39","author":"J Goswami","year":"2009","unstructured":"Goswami, J., Hernandez-Santos, N., Zuniga, L. A. & Gaffen, S. L. A bone-protective role for IL-17 receptor signaling in ovariectomy-induced bone loss. Eur. J.\u00a0Immunol. 39, 2831\u20132839 (2009).","journal-title":"Eur. J. Immunol."},{"key":"91_CR76","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1002\/jcb.24165","volume":"113","author":"CJ DeSelm","year":"2012","unstructured":"DeSelm, C. J. et al. IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J. Cell. Biochem. 113, 2895\u20132902 (2012).","journal-title":"J. Cell. Biochem."},{"key":"91_CR77","doi-asserted-by":"crossref","first-page":"330ra37","DOI":"10.1126\/scitranslmed.aad8996","volume":"8","author":"O Uluckan","year":"2016","unstructured":"Uluckan, O. et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci. Transl Med. 8, 330ra37 (2016).","journal-title":"Sci. Transl Med."},{"key":"91_CR78","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13075-016-0998-x","volume":"18","author":"AT Shaw","year":"2016","unstructured":"Shaw, A. T., Maeda, Y. & Gravallese, E. M. IL-17A deficiency promotes periosteal bone formation in a model of inflammatory arthritis. Arthritis Res. Ther. 18, 104\u2013113 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"91_CR79","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.archoralbio.2014.05.009","volume":"59","author":"YG Kim","year":"2014","unstructured":"Kim, Y. G. et al. IL-17 inhibits osteoblast differentiation and bone regeneration in rat. Arch. Oral Biol. 59, 897\u2013905 (2014).","journal-title":"Arch. Oral Biol."},{"key":"91_CR80","volume":"7","author":"T Ono","year":"2016","unstructured":"Ono, T. et al. IL-17-producing \u03b3\u03b4 T cells enhance bone regeneration. Nat. Commun. 7, 10928 (2016).","journal-title":"Nat. Commun."},{"key":"91_CR81","volume":"7","author":"D Nam","year":"2012","unstructured":"Nam, D. et al. T-Lymphocytes enable osteoblast maturation via IL-17F during the early phase of fracture repair. PLoS ONE 7, e40044 (2012).","journal-title":"PLoS ONE"},{"key":"91_CR82","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bone.2016.01.010","volume":"84","author":"M Croes","year":"2016","unstructured":"Croes, M. et al. Proinflammatory T cells and IL-17 stimulate osteoblast differentiation. Bone 84, 262\u2013270 (2016).","journal-title":"Bone"},{"key":"91_CR83","doi-asserted-by":"crossref","first-page":"R96","DOI":"10.1186\/ar2297","volume":"9","author":"T Yago","year":"2007","unstructured":"Yago, T. et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res. Ther. 9, R96 (2007).","journal-title":"Arthritis Res. Ther."},{"key":"91_CR84","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.4049\/jimmunol.181.2.1507","volume":"181","author":"JH Ju","year":"2008","unstructured":"Ju, J. H. et al. IL-23 induces receptor activator of NF-\u03baB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J. Immunol. 181, 1507\u20131518 (2008).","journal-title":"J. Immunol."},{"key":"91_CR85","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.imlet.2009.10.012","volume":"127","author":"X Li","year":"2010","unstructured":"Li, X. et al. IL-23 induces receptor activator of NF-\u03baB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-\u03baB signal pathways. Immunol. Lett. 127, 100\u2013107 (2010).","journal-title":"Immunol. Lett."},{"key":"91_CR86","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/eji.200838192","volume":"38","author":"L Chen","year":"2008","unstructured":"Chen, L., Wei, X. Q., Evans, B., Jiang, W. & Aeschlimann, D. IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-\u03baB (RANK) expression in myeloid precursor cells. Eur. J. Immunol. 38, 2845\u20132854 (2008).","journal-title":"Eur. J. Immunol."},{"key":"91_CR87","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4049\/jimmunol.1401013","volume":"194","author":"HS Shin","year":"2015","unstructured":"Shin, H. S. et al. Crosstalk among IL-23 and DNAX activating protein of 12\u2005kDa-dependent pathways promotes osteoclastogenesis. J. Immunol. 194, 316\u2013324 (2015).","journal-title":"J. Immunol."},{"key":"91_CR88","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00774-007-0766-8","volume":"25","author":"S Kamiya","year":"2007","unstructured":"Kamiya, S. et al. Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J. Bone Miner. Metab. 25, 277\u2013285 (2007).","journal-title":"J. Bone Miner. Metab."},{"key":"91_CR89","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.4049\/jimmunol.181.8.5720","volume":"181","author":"JM Quinn","year":"2008","unstructured":"Quinn, J. M. et al. IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J. Immunol. 181, 5720\u20135729 (2008).","journal-title":"J. Immunol."},{"key":"91_CR90","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4049\/jimmunol.1003986","volume":"187","author":"IE Adamopoulos","year":"2011","unstructured":"Adamopoulos, I. E. et al. IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J. Immunol. 187, 951\u2013959 (2011).","journal-title":"J. Immunol."},{"key":"91_CR91","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh, A. et al. Ustekinumab, an anti-IL-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann. Rheum. Dis. 73, 1000\u20131006 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"91_CR92","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ni.3579","volume":"18","author":"R Pfeifle","year":"2017","unstructured":"Pfeifle, R. et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat. Immunol. 18, 104\u2013113 (2017).","journal-title":"Nat. Immunol."},{"key":"91_CR93","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7651","volume":"6","author":"U Harre","year":"2015","unstructured":"Harre, U. et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat. Commun. 6, 6651 (2015).","journal-title":"Nat. Commun."},{"key":"91_CR94","first-page":"5950395","volume":"2017","author":"JR Zhang","year":"2017","unstructured":"Zhang, J. R. et al. Different modulatory effects of IL-17, IL-22, and IL-23 on osteoblast differentiation. Mediators Inflamm. 2017, 5950395 (2017).","journal-title":"Mediators Inflamm."},{"key":"91_CR95","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3389\/fimmu.2018.00885","volume":"9","author":"A Reinhardt","year":"2018","unstructured":"Reinhardt, A. & Prinz, I. Whodunit? The contribution of interleukin (IL)-17\/IL-22- producing \u03b3\u03b4 T cells, \u03b1\u03b2 cells T cells, and innate lymphoid cells to the pathogenesis of spondyloarthritis. Front. Immunol. 9, 885 (2018).","journal-title":"Front. Immunol."},{"key":"91_CR96","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3109\/08916934.2016.1166214","volume":"49","author":"J Karczewski","year":"2016","unstructured":"Karczewski, J., Dobrowolska, A., Rychlewska-Hanczewska, A. & Adamski, Z. New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis. Autoimmunity 49, 435\u2013450 (2016).","journal-title":"Autoimmunity"},{"key":"91_CR97","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar3781","volume":"14","author":"A Mitra","year":"2012","unstructured":"Mitra, A., Raychaudhuri, S. K. & Raychaudhuri, S. P. Functional role of IL-22 in psoriatic arthritis. Arthritis Res. Ther. 14, R65 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"91_CR98","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/art.40447","volume":"70","author":"L Yang","year":"2018","unstructured":"Yang, L. et al. Augmented Th17 differentiation leads to cutaneous and synovio-entheseal inflammation in a novel model of psoriatic arthritis. Arthritis Rheumatol. 70, 855\u2013867 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"91_CR99","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/art.33446","volume":"64","author":"KW Kim","year":"2012","unstructured":"Kim, K. W. et al. Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum. 64, 1015\u20131023 (2012).","journal-title":"Arthritis Rheum."},{"key":"91_CR100","first-page":"488","volume":"56","author":"AA El-Zayadi","year":"2017","unstructured":"El-Zayadi, A. A. et al. Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology 56, 488\u2013493 (2017).","journal-title":"Rheumatology"},{"key":"91_CR101","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/art.22758","volume":"56","author":"D McGonagle","year":"2007","unstructured":"McGonagle, D., Lories, R. J., Tan, A. L. & Benjamin, M. The concept of a \u201csynovio-entheseal complex\u201d and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 56, 2482\u20132491 (2007).","journal-title":"Arthritis Rheum."},{"key":"91_CR102","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2147\/DDDT.S164562","volume":"12","author":"B Lisowska","year":"2018","unstructured":"Lisowska, B., Kosson, D. & Domaracka, K. Lights and shadows of NSAIDs in bone healing: the role of prostaglandins in bone metabolism. Drug Des. Devel. Ther. 12, 1753\u20131758 (2018).","journal-title":"Drug Des. Devel. Ther."},{"key":"91_CR103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2018.02.002","volume":"57","author":"Z Wang","year":"2018","unstructured":"Wang, Z. et al. The positive effects of secreting cytokines IL-17 and IFN-\u03b3 on the early-stage differentiation and negative effects on the calcification of primary osteoblasts in vitro. Int. Immunopharmacol. 57, 1\u201310 (2018).","journal-title":"Int. Immunopharmacol."},{"key":"91_CR104","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten, D. et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373, 2534\u20132548 (2015).","journal-title":"N. Engl. J. Med."},{"key":"91_CR105","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun, J. et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann. Rheum. Dis. 76, 1070\u20131077 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"91_CR106","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/ard.2008.091793","volume":"68","author":"R Landewe","year":"2009","unstructured":"Landewe, R., Dougados, M., Mielants, H., van der Tempel, H. & van der Heijde, D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann. Rheum. Dis. 68, 863\u2013867 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"91_CR107","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-018-1653-5","volume":"20","author":"E Kampylafka","year":"2018","unstructured":"Kampylafka, E. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriaric arthritis by IL-17 blockade with secukinumab; results from the prospective PSARTROS study. Arthritis Res. Ther. 20, 153 (2018).","journal-title":"Arthritis Res. Ther."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0091-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0091-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0091-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T09:29:58Z","timestamp":1693906198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-018-0091-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,28]]},"references-count":107,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["91"],"URL":"https:\/\/doi.org\/10.1038\/s41584-018-0091-8","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,28]]},"assertion":[{"value":"28 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.M.G. declares that she has received research funding from AbbVie and Eli Lilly. G.S. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}